Navigation Links
Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
Date:4/18/2013

BEIJING, April 18, 2013  /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of vaccines in China, announced today that Fengcai Zhu, Deputy Director of the Jiangsu Provincial Center for Disease Prevention and Control, presented data regarding Sinovac's proprietary enterovirus 71 ("EV71") vaccine against hand, foot and mouth disease ("HFMD") at the 13th Annual World Vaccine Congress & Expo, taking place from April 16-18, 2013, in Washington D.C. Dr. Fengcai Zhu acted as a co-principal investigator in Sinovac's phase III trial for its EV71 vaccine.

Dr. Fengcai Zhu delivered a presentation entitled "The clinical evaluation of new vaccines in China," at 12:25 pm EDT on April 17, 2013. In his presentation, Dr. Fengcai Zhu discussed the efficacy and safety of the Company's EV71 vaccine. Data from the Phase III trial indicated that our EV71 vaccine had 95% efficacy against EV71-associated HFMD /herpangina, and 100% efficacy against EV71-associated hospitalization.  Herpangina is a painful mouth infection that can be caused by EV71.

There were no significant differences between the vaccine group and the placebo group for the adverse reaction symptoms and incident rate in the phase III trial.

The double-blinded, randomized, placebo controlled phase III clinical trial was conducted at three sites across China's Jiangsu province. Approximately 10,000 healthy infants completed the two-dose vaccination schedule (at day 0 and day 28) in the first quarter of 2012, prior to the HFMD epidemic season in China. Trial participants were then followed in an active monitoring period.

For more information about the 13th Annual World Vaccine Congress & Expo, visit the webpage (http://www.terrapinn.com/2013/world-vaccine-congress-washington/index.stm) or the event blog (http://blogs.terrapinn.com/vaccinenation).

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza and mumps, as well as animal rabies vaccine.  In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program.  The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program.  Sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot, and mouth disease), pneumococcal conjugate, pneumococcal polysaccharides, varicella and rubella.  Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac was also granted a license to commercialize seasonal flu vaccine in Mexico.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Helen Yang
Sinovac Biotech Ltd.
Tel:  +86-10-8279-9871
Fax:  +86-10-6296-6910
Email: ir@sinovac.com

Investors:
Stephanie Carrington
The Ruth Group
Tel:  +1-646-536-7017
Email: scarrington@theruthgroup.com

Media:
Aaron Estrada
The Ruth Group
Tel:  +1-646-536-7028
Email: aestrada@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Reports Unaudited Third Quarter 2012 Financial Results
2. Sinovac to Host Conference Call to Report Third Quarter 2012 Unaudited Financial Results
3. Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
4. Sinovac Holds 2012 Annual General Meeting of Shareholders
5. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
6. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
7. Sinovac Schedules 2012 Annual Meeting of Shareholders
8. Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
9. Sinovac Reports Unaudited First Quarter 2012 Financial Results
10. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
11. Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... France , Germany , Italy ... ). It includes a 10-year epidemiology forecast for the total prevalent ... sex in these markets. GD epidemiology report is written and developed by ... and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... 2016  The Senior Care Pharmacy Coalition (SCPC) ... Chairman Jason Chaffetz (R-UT) and Ranking ... hearing , "Developments in the Prescription Drug Market," ... questions about abusive pharmacy benefit manager (PBM) pricing ... Ranking Member Elijah Cummings (D-MD) are diligent, serious ...
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
Breaking Medicine Technology:
(Date:2/5/2016)... Seattle, WA (PRWEB) , ... February 05, 2016 ... ... consulting firm, ranked #3 in the 2015 Best in KLAS: Software & Services ... The annual Best in KLAS report independently ranks vendor performance by healthcare ...
(Date:2/5/2016)... ... , ... Stuart Bentkover, MD, FACS is thrilled to announce the ... effective tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts to ... has been approved by the Food and Drug Administration (FDA) as a safe and ...
(Date:2/5/2016)... ... ... In sleep, when the defenses of the day are at rest, rejected emotions ... disorders is significant self-criticism, and consequently these patients experience this disease with their feelings, ... for coping with this unease, but also leads to a reservoir of emotions that ...
(Date:2/5/2016)... Ramsey, NJ (PRWEB) , ... February 05, 2016 ... ... Optimizing Primary Care for Patients with Rare Diseases, a continuing medical education (CME) ... conference is the first of its kind—and a first for ACCORD, whose mission ...
(Date:2/5/2016)... ... 2016 , ... –This week, Atascadero water heater company First Call Plumbing ... To view the report, click here or see below. , There ... pros and cons, the type chosen is almost entirely up to personal preference. However, ...
Breaking Medicine News(10 mins):